Next 10 |
2024-04-15 17:21:24 ET Gainers: Macatawa Bank Corporation ( MCBC ) +38% . Biomea Fusion ( BMEA ) +5% . The RealReal ( REAL ) +4% . Cartesian Therapeutics ( RNAC ) +3% . Construction Partners ( ROAD ) +3% . Losers: Poseida...
2024-04-02 13:18:01 ET Biomea Fusion ( NASDAQ: BMEA ) shares fell on Tuesday as JPMorgan downgraded the biotech to Neutral from Overweight citing its financial issues and newly released data for the company’s lead asset BMF-219.... Read the full article on Seeking...
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...
2024-04-01 10:06:14 ET More on Biomea Fusion Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research Seeking Alpha’s Quant Rating on Biomea Fusion Read the full article on Seeking Alpha For further details see: Biomea Fusion GAAP EPS...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of be...
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After just a 4-week treatment period in type 2 diabetes patients, who had previ...
2024-03-26 16:42:37 ET Gainers: nCino ( NCNO ) +14% . Biomea Fusion ( BMEA ) +7% . Poseida Therapeutics ( PSTX ) +5% . Office Properties Income ( OPI ) +5% . Canopy Growth Corporation ( CGC ) +4% . Losers: Bow...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17 th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2 Diabetes Patients in COVALENT-111 are displaying improved glycemic cont...
News, Short Squeeze, Breakout and More Instantly...
Biomea Fusion Inc. Company Name:
BMEA Stock Symbol:
NASDAQ Market:
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of be...
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After just a 4-week treatment period in type 2 diabetes patients, who had previ...